CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
Introduction. JAK2V617F mutation is detected in approximately 50 % of patients with essential thrombocytosis (ET) and primary myelofibrosis (PMF). In 2013 most of the JAK2 negative patients showed mutations in the CALR gene. Diagnostic value of JAK2 and CALR mutations is high, but their prognostic s...
Main Authors: | E. G. lisina, N. T. Siordiya, P. A. Butylin, A. A. Silyutina, N. M. Matyukhina, O. M. Senderova, E. S. Fokina, V. A. Ovsepyan, E. G. Lomaia, A. Yu. Zaritskiy |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-10-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/253 |
Similar Items
-
Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post‐essential thrombocythemia myelofibrosis: A case report
by: Mahija Cheekati, et al.
Published: (2024-04-01) -
Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
by: Lasse Kjær, et al.
Published: (2023-05-01) -
Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01) -
Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
by: Arturo Bonometti, et al.
Published: (2023-04-01) -
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease
by: Magda Zanelli, et al.
Published: (2024-03-01)